nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

24.01.2023 | short review

Update on systemic therapy for clear cell renal cell carcinoma

verfasst von: Dr. Josef Mühlmann

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Summary

The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 years later, both demonstrating significantly improved overall survival (OS) rates across all RCC risk categories. Currently, combination therapies represent the standard-of-care in the first-line setting of clear cell RCC in almost all cases. In this short review article, the most recent therapeutic advances in early and advanced stage of clear cell RCC are summarized.

Vorheriger Artikel Best of hematology—2021

Nächster Artikel Biomarkers and translational research approaches in breast cancer—an update

Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–94.CrossRefPubMed

Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. J Clin Oncol. 2022;40(6_suppl):290.CrossRef

Motzer RJ, Russo P, Guenwald V, et al. Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Ann Oncol. 2022;33(7_suppl):S808–S69.

Bex A, Uzzo R, Karam JA, Master VA, et al. IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Ann Oncol. 2022;33(7_suppl):S808–S69.

Allaf M, Kim SE, Harshman LC, McDermott DF, et al. Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol. 2022;33(7_suppl):S808–S69.

Powels T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511–9.CrossRef

Motzer RJ, Tannir NM, McDermott DF, et al. Conditional survival and 5‑year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Ann Oncol. 2021;32(suppl_5):S678.

Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5‑year minimum follow-up. J Clin Oncol. 2022;40(6_suppl):352.CrossRef

Rini BL, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. J Clin Oncol. 2021;39(15_suppl):4500.CrossRef

10.

Powels T, Choueiri TK, Burotto M, Escudier B, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):350.CrossRef

11.

Motzer R, Alekseev B, Rha SY, Porta C, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300.CrossRefPubMed

12.

Choueiri TK, Powels TB, Albiges L, Burotto M, et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33(7_suppl):S808–S69.

13.

Recio-Boiles A, et al. Network meta-analysis (NMA) of second-line (2L) treatment options in metastatic renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):337.CrossRef

14.

Motzer RJ, Hutson TE, Glen H, Michaelson MD, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.CrossRefPubMed

15.

Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90.CrossRefPubMed

16.

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036–46.CrossRefPubMedPubMedCentral

17.

Bauer TM, Chouieri TK, Papadopoulos KP, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma: updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273.CrossRef

18.

Choueiri TK, Albiges L, Fan L, Perini RF, et al. Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2020;38(15_suppl):TPS5094.CrossRef

19.

Calvo E, Boni V, Chaudhry A, Debruyne PR, et al. Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY‑1. J Clin Oncol. 2022;40(6_suppl):330.CrossRef

Titel: Update on systemic therapy for clear cell renal cell carcinoma
verfasst von: Dr. Josef Mühlmann
Publikationsdatum: 24.01.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00867-w

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Total neoadjuvant therapy in rectal cancer

Efficacy of dual checkpoint-blockade in solid tumors, part 1

Dual checkpoint-blockade in urothelial carcinoma—when is it so far

Radiooncology and nuclear medicine

Barriers to patient access of CAR T cell therapies in Austria

Cutaneous lymphomas—fast facts about an orphan disease—a short review